Medicine Matters oncology

Welcome

We provide news, expert interviews, and educational resources to help you keep up with the latest developments in oncology

Learn more

Long-term effects of COVID-19 not uncommon in cancer patients

Combining LuPSMA with pembrolizumab ‘promising’ for mCRPC

MONALEESA-2 update demonstrates ribociclib plus letrozole OS benefit

CASPIAN update cements durvalumab–chemo as standard of care for extensive-stage SCLC

Adequate response to COVID-19 vaccine in people receiving anticancer therapy

Drug-free interval feasible in metastatic RCC

IN FOCUS | ESMO Congress 2021

18-09-2021 | ESMO 2021 | Conference coverage | Video

Promising early results for cetrelimab plus erdafitinib reported for advanced UC

Thomas Powles explains why the interim results of the NORSE trial of first-line cetrelimab plus erdafitinib in FGFR-altered advanced urothelial cancer not only justify its continuance, but also point to the need for larger studies of the combination in this setting.

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

No new safety signals for neoadjuvant, maintenance atezolizumab in mesothelioma

Flexibility positively impacts lung cancer clinical trial participation in COVID-19 era

Pretreatment ctDNA levels may predict survival in neoadjuvant-treated NSCLC patients

Atezolizumab plus chemotherapy feasible for NSCLC with brain metastases

No OS benefit of lurbinectedin plus doxorubicin in relapsed SCLC

Durvalumab–tremelimumab plus chemo ‘a potential new first-line option’ for metastatic NSCLC

FDA approves mobocertinib for advanced NSCLC with EGFR exon 20 insertions

No overall survival benefit with first-line bevacizumab–erlotinib in EGFR-mutant NSCLC

Single-fraction SABR may be preferred for lung oligometastases

Significant declines in cancer diagnoses during first year of COVID-19 pandemic

Chemoimmunotherapy efficacy unaffected by antibiotic use in advanced NSCLC

Hypofractionated image-guided RT not the answer for chemoradiotherapy-ineligible NSCLC

IN FOCUS | Lung & thoracic cancers

09-09-2021 | WCLC 2021 | Conference coverage | News

Durvalumab–tremelimumab plus chemo ‘a potential new first-line option’ for metastatic NSCLC

The addition of durvalumab plus tremelimumab to chemotherapy significantly improves the outcomes of people with untreated metastatic non-small-cell lung cancer, shows the POSEIDON trial.

IN FOCUS | Genitourinary cancers

08-09-2021 | Prostate cancer | News

PRONOUCE fails to resolve CV safety questions for GnRH antagonists, agonists

Slow recruitment and low event rates have led to early termination of the PRONOUNCE trial, which hoped to determine the relative cardiovascular safety of gonadotropin-releasing hormone antagonists and agonists in men with prostate cancer.

Stay informed with Medicine Matters

Get the latest developments in breast, lung, & GU cancers delivered straight to your inbox

Residual cancer burden may predict treatment efficacy in breast cancer

Surgery extent impacts long-term QoL in young breast cancer survivors

Significant declines in cancer diagnoses during first year of COVID-19 pandemic

Cardioprotection worthwhile in anthracycline-treated breast cancer

Definition of breast cancer HR-positivity questioned

COVID-19-related drop in breast cancer screening may worsen pre-existing disparities

IN FOCUS | Breast cancer

09-08-2021 | Breast cancer | News

Statins linked to improved TNBC survival

Statin use in the 12 months after diagnosis of early-stage triple-negative breast cancer is associated with improved survival in older women, findings indicate.

IN FOCUS | COVID-19 & cancer

27-08-2021 | COVID-19 | News

PTSD not uncommon in cancer patients during COVID-19 pandemic

Around a fifth of people with cancer included in the French COVIPACT study reported symptoms consistent with post-traumatic stress disorder during the first national lockdown in response to the COVID-19 outbreak, find the investigators.